Navigation Links
Nektar Therapeutics Reports First Quarter 2009 Financial Results
Date:5/6/2009

e accounts receivable 5,365 7,597 Decrease (increase) in inventories (4,073) 1,160 Decrease (increase) in prepaids and other assets 496 2,044 Increase (decrease) in accounts payable (8,095) (2,033) Increase (decrease) in accrued compensation (6,133) (3,932) Increase (decrease) in accrued clinical trial expenses (2,640) 86 Increase (decrease) in accrued expenses to contract manufacturers - (31,994) Increase (decrease) in accrued expenses 3,364 (123) Increase (decrease) in deferred revenue (3,029) (1,200) Increase (decrease) in other liabilities (1,897) (2,761) ------ ------ Net cash used in operating activities (42,394) (64,972) Cash flows from investing activities: Purchases of property and equipment (5,104) (5,281) Purchases of investments (85,298) (156,092) Maturities of investments 104,458 186,758 Transaction costs from Novartis pulmonary asset sale (4,766) - ------ --- Net cash provided by investing activities 9,290 25,385 Cash flows used in financing activities: Proceeds from issuances of common stock 61 371 Payments of loan and capital lease obligations (302) (411) ---- ---- Net cash used in financing activities
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... HEAD, N.J. , June 1, 2015  The ... launch a national innovative science curriculum for high school ... at the 16 th annual LIFE Event (LPGA ... at Mountain Ridge Country Club in West ... of the LPGA,s biggest stars raised more than $500,000 ...
(Date:6/1/2015)... LANSING, Mich. , June 1, 2015  Neogen Corporation ... the assets of Sterling Test House, a leading commercial food ... and that the acquired laboratory will serve as a base ... . Sterling Test House was ... virtually all of the food safety and water quality testing ...
(Date:6/1/2015)... June 1, 2015   Epic Sciences, Inc. , ... and offerings to personalize and advance the treatment and ... the available credit under its existing credit facility with ... increases the available capacity of the facility from $5 ... by 27 months to April 1, 2019.  The availability ...
(Date:6/1/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/5j2hpk/2015_strategies ... "2015 Strategies in the US Point-of-Care/POC ... offering. This new 373-page report ... analysis of the POC clinical chemistry market, ... technological trends, competitive landscape, and emerging opportunities ...
Breaking Biology Technology:Val Skinner Foundation Announces Partnership With Discovery Education 2Neogen acquires India food safety company 2Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... July 30 /PRNewswire-Asia/ -- Eli Lilly & Company ... they have,reached an amicable resolution of all ongoing ... and sale of gemcitabine,hydrochloride around the world. , ... settlement, Lilly has granted ScinoPharm a royalty bearing,license ...
... TOKYO, July 30 With a ... Pharmaceutical Co. Ltd., a subsidiary of,the Zydus group, one of ... looking to give a big boost to its operations,in the ... market in Japan is estimated at $ 60 bn the ...
... viable solar power cellscheap, flexible and easy to makehas ... of recent work* at the National Institute of Standards ... of the complex organic films at the heart of ... molecules to capture sunlight and convert it into electricity, ...
Cached Biology Technology:Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation 2"Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan" - Dr. Kailash Sharma, President, Japan Operations, Zydus Cadila 2NIST scientists study how to stack the deck for organic solar power 2
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... Researchers presented Phase III efficacy data from the GeparQuinto ... in combination with chemotherapy for patients with early breast ... Cancer Symposium, held Dec. 8-12. "We had ... combination of chemotherapy, trastuzumab, with the new combination of ...
... the World Health Organization Collaborating Centre for Metabolic Bone Diseases ... a FRAX calculator for Singapore. The FRAX tool ... by the WHO to help evaluate patients at low, medium ... factors, with or without the use of bone mineral density ...
... in recent years to reduce carbon emissions by increasing efficiency ... carbon emissions in China have grown dramatically during that same ... questions about who is to blame when the coal China ... are produced to manufacture goods exported back to places with ...
Cached Biology News:Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer 2WHO Fracture Risk Assessment Tool (FRAX) newly released for Singapore 2
... Immulon 2HB ELISA strips, ... increased binding affinity for hydrophilic proteins ... works well for reagent injection while ... Each strip accomodates 12 ...
...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
... The 2.0 network client/server version of Freezerworks ... workflow in high-volume labs and facilitates the sharing ... to share sample information. ... PowerPC (100MHz, PPC 601); 13 in monitor with ...
Biology Products: